Septerna Reports Positive Phase 1 Data for SEP-631, Advancing to Phase 2b for Chronic Spontaneous Urticaria

summarizeSummary

Septerna announced positive Phase 1 clinical trial results for its lead candidate, SEP-631, demonstrating favorable safety, pharmacokinetics, and clinical proof-of-mechanism. The company plans to advance SEP-631 into a Phase 2b trial for chronic spontaneous urticaria in the second half of 2026.

check_boxKey Events

• Positive Phase 1 Results for SEP-631

  Septerna announced positive data from its Phase 1 clinical trial for SEP-631, an oral MRGPRX2 NAM for mast cell-driven diseases. The trial assessed safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) activity in healthy volunteers.

• Favorable Safety and Pharmacokinetics

  SEP-631 was well-tolerated across all doses, with an adverse event profile comparable to placebo and no severe or serious adverse events. It demonstrated a PK profile supporting convenient once-daily oral dosing with an approximate 24-hour half-life and no clinically meaningful food effect.

• Clinical Proof-of-Mechanism Achieved

  The drug produced robust, dose-dependent suppression of icatibant-induced skin wheal formation, an established measure of mast cell activation, with complete inhibition observed at doses as low as 10 mg once daily. This provides clinical proof-of-mechanism for MRGPRX2 pathway inhibition.

• Phase 2b Trial Planned for H2 2026

  Based on these results, Septerna plans to initiate a Phase 2b clinical trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of 2026, following the completion of ongoing long-term toxicology studies. The company is also evaluating other mast cell-driven indications.

auto_awesomeAnalysis

Septerna's announcement of positive Phase 1 results for SEP-631 is a significant de-risking event for the clinical-stage biotechnology company. The robust safety profile, favorable pharmacokinetics, and clear clinical proof-of-mechanism validate the drug candidate and the company's Native Complex Platform. The outlined plan to initiate a Phase 2b trial in chronic spontaneous urticaria (CSU) in the second half of 2026 provides a clear development pathway for a potentially differentiated oral treatment in a disease with high unmet medical need. This progress could significantly enhance investor confidence in Septerna's pipeline and technology.